Indivior, a pharmaceutical firm specializing in opioid addiction treatments, plans to delist from the London Stock Exchange ...

Indivior is set to delist from the London Stock Exchange after a sharp decline in the value of its shares and a management ...

Drugmaker Indivior has announced plans to cancel its secondary listing in London, just a year after moving its primary ...

Drug maker Indivior (INDV.L) has announced plans to delist its shares from the London Stock Exchange (LSE), marking the ...

The British pharmaceuticals company said the US exchange offers the ‘most attractive and valuable opportunity set’ ...

As it works to send opioid use disorder (OUD) treatment Sublocade back into its prior growth territory, Indivior is switching ...

Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company ...

Wise Plc is planning to list its shares in the US, the latest loss for London’s stock market after companies worth roughly ...

Pharmaceutical firm Indivior has announced it will soon delist from the London Stock Exchange, keeping its primary listing on ...

Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align ...